Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
My thoughts are SP will move in the following order
- commencement of clinical trial which has been long overdue - we are now in Q2. Last clinical trial this was circa a pound
- positive results from clinical trial - we will be in lala land here.
there might be other side moves i.e. the other indication of lupuzor e.t.c
Imagine what would happen when the clinical trial commences, and if the results this time are positive. Which hopefully they should be as the population would be based off the previous clinical trial. The subpopulation in that study was positive. The sky is the limit guys
@cauldstream7 let's be frank..this is incompetent by Tim and the guys. The delay is inexcusable. They knew for months that this trial was incoming. They should have placed a tender ages ago. I really hope that isn't the case. It wouldn't make any sense. If this is the case then expect an rns next year regarding commencement of the trial. Because it takes time. They need to put agreements in place and then recruit patients. I doubt this the case if Tim said by q4 this year.
Thanks @oscar22 great explanation. It's definitely a positive news. But just not the one the market is looking for. In the long term it does make immupharma more attractive particularly if incanthera do well. None the less we need to hear that the trial has commenced and is on track
Can someone explain the positive of this news. I think main issue is the market is waiting for the promised commencement of the clinical trial. It has yet to come. It's inexcusable really. Imm should have been on point, they knew ages ago. It's also not their first trial
@maidit. It hasn't taken a week. Don't confuse the P140 platform aimed at Lupus to that aimed at CIPD. We are still waiting on the news for the CIPD. However, I agree momentum is building. I also think the CIPD process meetings will be quicker, by now Imm would have learnt from previous submissions